continue to site
"Trust in the Lord with all thine heart; and lean not unto thine own understanding. In all thy ways acknowledge him, and he shall direct thy paths."
- Proverbs 3:5-6
December 2023
health living travel food shop events blog
home health living travel food shop events jobs trending magazine Contact Us Advertise
Arizona Oncology Set to Expand to New Location in Prescott
By Molly Hammond - Tuesday Sep 20, 2022
Arizona Oncology, one of the largest cancer centers in Arizona with more than 70 physicians, will break ground on its new Prescott practice on Saturday, Sept. 24.

The new 22,000 square-foot comprehensive care center, located at 5430 Landmark Lane, Prescott, will provide radiation and chemotherapy services under one roof, as well as provide diagnostic imaging, surgery, genomic testing and more.

“Arizona Oncology is committed to evolving our practices to best fit the needs of our patients,” said Iyad Hamarneh, Medical Oncologist with Arizona Oncology. “While we’ve outgrown this facility, we look forward to growing with the Prescott community.”

Arizona Oncology plans to bring a 34-chair infusion area with outdoor garden space to the location. It will hire two additional doctors and medical teams, bringing additional collaboration between medical teams and patients. The facility will also include 15 total medical, gynecologic and radiation oncology exam rooms, along with a PET-CT imaging room. Future additions include two linear accelerators for external beam radiation treatments.

“Cancer is a tough disease to deal with alone, let alone the difficulties of navigating several different treatments at multiple facilities,” said Hamarneh. “This tends to be the ‘normal’ medical experience for patients. We wanted to change that experience into a more efficient process. In building a new facility, we’re able to provide all of our services under one roof so patients can experience more collaborative medical care.”

Arizona Oncology has been caring for the Prescott community for many years. Physician specialists currently practicing in Prescott who will transfer to the new location include Medical Oncologists and Hematologists Dr. Allan Espinoza, Dr. Iyad Hamarneh, Dr. Alan Langerak and Radiation Oncologist Dr. Marshall Davis.

Additionally, a welcoming staff of lab specialists, pharmacists, nutritionists and other medical professionals are there to create a seamless patient experience.

The Prescott office joins Arizona Oncology’s other statewide locations in Glendale, Goodyear, Green Valley, Phoenix, Prescott Valley, Scottsdale and Tucson.

For more information about new and existing locations, visit

About Arizona Oncology

Arizona Oncology is one of the largest medical groups in Arizona. With more than 75 practicing physicians devoted exclusively to providing comprehensive, compassionate and high-quality cancer care, Arizona Oncology specializes in Medical, Gynecologic, and Radiation Oncology, Hematology, Stem Cell Transplant, Research, Genetic Risk Assessment and patient ancillary programs. The physicians and their staff treat patients in many communities throughout the state including: Chandler, Cottonwood, Deer Valley, Estrella, Flagstaff, Glendale, Green Valley, Nogales, Peoria, Phoenix, Prescott Valley, Safford, Scottsdale, Sedona, and Tucson.

Arizona Oncology believes it is beneficial to provide cancer therapies in a community setting, close to patients' homes and support systems. The physicians are supported by a talented clinical team sensitive to the needs of cancer patients and their caregivers. For more information, visit

Arizona Oncology is united in healing with The US Oncology Network, one of the nation’s largest networks of integrated community-based oncology practices dedicated to advancing high-quality, evidence-based cancer care. As an affiliate of The US Oncology Network, Arizona Oncology is united with more than 1,000 physicians nationwide. Arizona Oncology participates in clinical trials through US Oncology Research, which has played a role in nearly 60 FDA-approved cancer therapies, nearly one-third of all cancer therapies approved by the FDA to date. For more information, visit